This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
30 December 1998
I wish to point out that I no longer stand by the views reported in my News and Views article “Immunology: Ways around rejection” (Nature 377, 576–577; 1995), which dealt with a paper in the same issue (“A role for CD95 ligand in preventing graft rejection” by D. Bellgrau et al. — Nature 377, 630–635; 1995).
References
Selawry, H. P. & Cameron, D. F. Cell Transplant. 2, 123–129 (1993).
Bellgrau, D. et al. Nature 377, 630–632 (1995).
Takahashi, T. et al. Int. Immun. 6, 1567–1574 (1994).
Barker, C. F. & Billingham, R. E. Adv. Immun. 25. 1–54 (1977).
Head, J. R., Neaves, W. B. & Billingham, R. E. Transplantation 35, 91–95 (1983).
Miyawaki, T. et al. J. Immun. 149, 3753–3758 (1992).
Itoh, N. et al. Cell 66, 233–243 (1991).
Alderson, M. R. et al. J. exp. Med. 181, 71–77 (1995).
Nagata, S. & Golstein, P. Science 267, 1449–1456 (1995).
McCurry, K. R. et al. Nature Med. 1, 423–427 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vaux, D. Ways around rejection. Nature 377, 576–577 (1995). https://doi.org/10.1038/377576a0
Issue Date:
DOI: https://doi.org/10.1038/377576a0
This article is cited by
-
Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape
Nature Medicine (2000)
-
Apoptosis-related proteins, BCL-2, BAX, FAS, FAS-L and PCNA in liver biopsies of patients with chronic hepatitis B virus infection
Pathology & Oncology Research (2000)
-
Correction: Immunology: Ways around rejection
Nature (1998)
-
CD95 ligand in graft rejection
Nature (1996)